Literature DB >> 33782915

The need to prioritize research, policy, and practice to address the overdose epidemic in smaller settings in Canada.

Geoff Bardwell1,2, Leslie Lappalainen3,4.   

Abstract

The majority of research and policy directives targeting opioid use and overdose prevention are based in larger urban settings and not easily adaptable to smaller Canadian settings (i.e., small- to mid-sized cities and rural areas). We identify a variety of research and policy gaps in smaller settings, including limited access to supervised consumption services, safer supply and novel opioid agonist therapy programs, as well as housing-based services and supports. Additionally, we identify the need for novel strategies to improve healthcare access and health outcomes in a more equitable way for people who use drugs, including virtual opioid agonist therapy clinics, episodic overdose prevention services, and housing-based harm reduction programs that are better suited for smaller settings. These programs should be coupled with rigorous evaluation, in order to understand the unique factors that shape overdose risk, opioid use, and service uptake in smaller Canadian settings.

Entities:  

Keywords:  Opioid agonist therapy; Opioid overdose prevention; Research; Rural health; Smaller settings; Supervised consumption services

Mesh:

Year:  2021        PMID: 33782915      PMCID: PMC8225779          DOI: 10.17269/s41997-021-00504-9

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  7 in total

1.  Assessing support for supervised injection services among community stakeholders in London, Canada.

Authors:  Geoff Bardwell; Ayden Scheim; Sanjana Mitra; Thomas Kerr
Journal:  Int J Drug Policy       Date:  2017-06-27

2.  Injectable opioid agonist treatment for opioid use disorder: a national clinical guideline.

Authors:  Nadia Fairbairn; Josey Ross; Michael Trew; Karine Meador; Jeff Turnbull; Scott MacDonald; Eugenia Oviedo-Joekes; Bernard Le Foll; Marie-Ève Goyer; Michel Perreault; Christy Sutherland
Journal:  CMAJ       Date:  2019-09-23       Impact factor: 8.262

3.  'Small communities, large oversight': The impact of recent legislative changes concerning supervised consumption services on small communities in Ontario, Canada.

Authors:  Cayley Russell; Sameer Imtiaz; Farihah Ali; Tara Elton-Marshall; Jürgen Rehm
Journal:  Int J Drug Policy       Date:  2020-06-18

4.  Correlates of take-home naloxone kit possession among people who use drugs in British Columbia: A cross-sectional analysis.

Authors:  Amina Moustaqim-Barrette; Kristi Papamihali; Alexis Crabtree; Brittany Graham; Mohammad Karamouzian; Jane A Buxton
Journal:  Drug Alcohol Depend       Date:  2019-10-07       Impact factor: 4.492

Review 5.  Supervised injection facilities in Canada: past, present, and future.

Authors:  Thomas Kerr; Sanjana Mitra; Mary Clare Kennedy; Ryan McNeil
Journal:  Harm Reduct J       Date:  2017-05-18

6.  Mobile supervised consumption services in Rural British Columbia: lessons learned.

Authors:  Silvina C Mema; Gillian Frosst; Jessica Bridgeman; Hilary Drake; Corinne Dolman; Leslie Lappalainen; Trevor Corneil
Journal:  Harm Reduct J       Date:  2019-01-10

7.  COVID-19 and overdose prevention: Challenges and opportunities for clinical practice in housing settings.

Authors:  Laura MacKinnon; M Eugenia Socías; Geoff Bardwell
Journal:  J Subst Abuse Treat       Date:  2020-10-04
  7 in total
  2 in total

Review 1.  Barriers and facilitators to opioid agonist therapy in rural and remote communities in Canada: an integrative review.

Authors:  Em M Pijl; Abeer Alraja; Elsie Duff; Carol Cooke; Stephen Dash; Nichole Nayak; Jesse Lamoureux; Ginette Poulin; Erin Knight; Ben Fry
Journal:  Subst Abuse Treat Prev Policy       Date:  2022-08-26

2.  Clinical outcomes and health care costs among people entering a safer opioid supply program in Ontario.

Authors:  Tara Gomes; Gillian Kolla; Daniel McCormack; Andrea Sereda; Sophie Kitchen; Tony Antoniou
Journal:  CMAJ       Date:  2022-09-19       Impact factor: 16.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.